Home > Healthcare > Drug Device Combination > Therapeutic Systems > Dacryocystitis Market

Dacryocystitis Market Share

Report ID: GMI9588
Published Date: May 2024
Report Format: PDF

Download Free Sample

Dacryocystitis Market Share

The market is highly fragmented due to the presence of many established and small vendors offering generics and surgical supplies. The generic manufacturers are offering a variety of formulations and types of dacryocystitis medications. Established vendors are outsourcing the medication and surgical supplies manufacturing to the contract manufacturers based in developing countries such as India and China, to reduce the overall manufacturing cost. Furthermore, established companies have significant experience and expertise with marketing and sales of dacryocystitis treatment products, which is contributing to the leading market share of established players.

Dacryocystitis Market Companies

Prominent players operating in the dacryocystitis industry include:

AbbVie Inc. (Allergan)
Alcon Inc.
Aurolab
Bausch Health Companies Inc.
Bayer AG
BVM Medical Limited
F. Hoffmann-La Roche Ltd (Genentech, Inc.)
FCI Ophthalmics
Gunther Weiss Scientific Glassblowing Co., Inc.
Heart Medical Europe BV
Kaneka Corporation
Merck & Co., Inc.
Novartis AG
Pfizer Inc.
Regeneron Pharmaceuticals Inc.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The dacryocystitis market size was valued at USD 40.6 million in 2023 and is anticipated to grow at 5.2% CAGR from 2024 – 2032, owing to the increasing prevalence of chronic and congenital dacryocystitis.

The surgery segment in the market held 62.2% revenue share in 2023, as it offers long-term management of the condition and high success rate.

North America dacryocystitis market held 41.6% share in 2023 and will generate a revenue of USD 25.7 million by 2032, attributed to the presence of advanced treatment facilities for offering minimally invasive treatment options, such as endoscopic dacryocystorhinostomy.

AbbVie Inc. (Allergan), Alcon Inc., Aurolab, Bausch Health Companies Inc., Bayer AG, BVM Medical Limited, F. Hoffmann-La Roche Ltd (Genentech, Inc.), FCI Ophthalmics, Gunther Weiss Scientific Glassblowing Co., Inc., Heart Medical Europe BV, and Kaneka Corporation.